VYNE Therapeutics (VYNE) Receivables - Other (2020 - 2021)

VYNE Therapeutics (VYNE) posted Receivables - Other of $5.5 million for Q4 2021, down 24.66% on a QoQ basis from $7.3 million in Q3 2021, and down 5.17% year-over-year from $5.8 million in Q4 2020.

VYNE Therapeutics (VYNE) Receivables - Other (2020 - 2021) Analysis & Trends

VYNE Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $5.5 million for Q4 2021.

  • Quarterly Receivables - Other fell 5.17% year-over-year to $5.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.5 million (down 5.17% YoY) and the FY2021 annual result came in at $5.5 million, down 5.17% from the prior year.
  • Receivables - Other was $5.5 million for Q4 2021 at VYNE Therapeutics, down from $7.3 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $8.1 million in Q1 2021 and bottomed at $4.0 million in Q2 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2021 5.50 Mn
Dec 31, 2021 5.50 Mn
Sep 30, 2021 7.30 Mn
Sep 30, 2021 7.30 Mn
Jun 30, 2021 7.60 Mn
Jun 30, 2021 7.60 Mn
Mar 31, 2021 8.10 Mn
Mar 31, 2021 8.10 Mn
Dec 31, 2020 5.80 Mn
Dec 31, 2020 5.80 Mn
Sep 30, 2020 5.60 Mn
Sep 30, 2020 5.60 Mn
Jun 30, 2020 4.00 Mn
Jun 30, 2020 4.00 Mn